Skip to main content

MCRPC

3
Pipeline Programs
5
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Hinova Pharmaceuticals
Hinova PharmaceuticalsChina - Chengdu
1 program
1
HC-1119Phase 31 trial
Active Trials
NCT03851640Recruiting417Est. Sep 2025
TYK Medicines
TYK MedicinesChina - Shanghai
1 program
1
TYK-00540Phase 1/21 trial
Active Trials
NCT07104643Not Yet Recruiting48Est. Nov 2026
Zenith Epigenetics
Zenith EpigeneticsCA - San Francisco
1 program
1
ZEN003694Phase 1/21 trial
Active Trials
NCT04145375Enrolling By Invitation40Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hinova PharmaceuticalsHC-1119
TYK MedicinesTYK-00540
Zenith EpigeneticsZEN003694

Clinical Trials (3)

Total enrollment: 505 patients across 3 trials

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Start: Apr 2019Est. completion: Sep 2025417 patients
Phase 3Recruiting

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

Start: Aug 2025Est. completion: Nov 202648 patients
Phase 1/2Not Yet Recruiting

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Start: Nov 2019Est. completion: Dec 202640 patients
Phase 1/2Enrolling By Invitation

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 505 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.